Hand Eczema Clinical Trial
Official title:
LEO19123 Cream in the Treatment of Hand Eczema
To compare the efficacy and safety of two different dose combinations of LEO19123 cream (calcipotriol and LEO80122) with LEO19123 cream vehicle for 3 weeks in the treatment of patients with hand eczema.
Status | Completed |
Enrollment | 75 |
Est. completion date | March 2007 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Clinical diagnosis of hand eczema with or without atopic etiology/background - Investigator.s Global Assessment of disease severity graded as at least mild at Visit 1 - Patients should be Caucasian males aged from 18 years - Attending a hospital outpatient clinic or the private practise of a dermatologist. - Following verbal and written information about the trial, the patient must provide signed and dated informed consent before any trial related activity is carried out, including activities relating to wash-out periods. Exclusion Criteria: - Systemic treatment with immunosuppressive drugs (e.g. methotrexate, cyclosporine, azathioprine) or corticosteroids within 4 weeks prior to randomisation. (Inhaled or intranasal steroids for asthma or rhinitis may be used). - PUVA or UVB therapy on the hands within 4 weeks prior to randomisation. - Topical treatment with immunomodulators (pimecrolimus, tacrolimus) or corticosteroids from WHO groups III or IV on the hands within 2 weeks prior to randomisation. - Other topical therapy on the hands (except for the use of emollient) within 1 week prior to randomisation. - Use of other treatment (drug, non-drug) on the hands during the trial except for the use of investigational product and emollient. - Concurrent skin diseases on the hands. - Current diagnosis of exfoliative dermatitis. - Significant clinical infection (impetiginised hand eczema) on the hands, which requires antibiotic treatment. - Known or suspected hypersensitivity to component(s) of the investigational product. - Positive patch test as defined in protocol - Known or suspected severe renal insufficiency or severe hepatic disorders. - Patients with history/signs/symptoms suggestive of an abnormality of calcium homeostasis associated with clinically significant hypercalcaemia. - Patients with history of cancer except for basal cell carcinoma. - Current participation in any other interventional clinical trial. - Patients who have received treatment with any nonmarketed drug substance (i.e. an agent which has not yet been made available for clinical use following registration) within 4 weeks prior to randomisation. - Previously randomised in this study. - Patients known or, in the opinion of the investigator, is unlikely to comply with the Clinical Study Protocol (e.g. alcoholism, drug dependency, or psychotic state). |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United Kingdom | Queen's Medical Centre | Nottingham |
Lead Sponsor | Collaborator |
---|---|
LEO Pharma |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Proof of concept | |||
Secondary | Safety |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00576550 -
A Randomised Trial of a Moisturising Cream in Preventing Recurrence of Hand Eczema
|
Phase 4 | |
Completed |
NCT05763914 -
A 24-week Single-blind Trial of Prevention of Hand Eczema in Cleaners
|
N/A | |
Recruiting |
NCT03026946 -
Alitretinoin vs Cyclosporine in Severe Recurrent Vesicular Hand Eczema
|
Phase 3 | |
Recruiting |
NCT03026907 -
Alitretinoin vs Azathioprine in Severe Non-hyperkeratotic Hand Eczema
|
Phase 3 | |
Completed |
NCT00488241 -
Multicenter Clinical Study to Examine the Efficacy and Safety of Zarzenda in Patients With Hand Eczema
|
Phase 4 | |
Active, not recruiting |
NCT05906628 -
Topical Ruxolitinib Evaluation in Chronic Hand Eczema
|
Phase 2 | |
Terminated |
NCT01826630 -
A Study to Assess CLn® BodyWash for Reducing Skin Fauna in Patients With Hand Eczema
|
N/A | |
Recruiting |
NCT04449575 -
Hand Eczema in the Health Care Sector
|
||
Withdrawn |
NCT05219864 -
Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 1
|
Phase 3 | |
Completed |
NCT01591785 -
Treatment of Staphylococcus Aureus Colonization in Hand Eczema
|
N/A | |
Completed |
NCT00826592 -
Comparison of Video-Based Versus Written Patient Education on Atopic Dermatitis
|
N/A | |
Completed |
NCT02664805 -
Proof of Concept, Twice Daily Applications of LEO 124249 Ointment in the Treatment of Chronic Hand Eczema
|
Phase 2 | |
Completed |
NCT05471934 -
Satisfaction Survey - Cicaplast Mains
|
||
Active, not recruiting |
NCT04512339 -
Dupilumab in Severe Chronic Hand Eczema
|
Phase 2 | |
Completed |
NCT04375410 -
Consequences of Intensified Handwash and Hand Disinfection Among Children During the COVID19 Pandemic
|